STRYKER CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 336.8 USD | +0.58% |
|
+0.24% | +12.49% |
| Apr. 15 | Truist Securities Adjusts Stryker Price Target to $364 From $345 | MT |
| Apr. 15 | BTIG Adjusts Stryker's Price Target to $366 From $353 | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company returns high margins, thereby supporting business profitability.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 33.53 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +12.49% | 127B | A- | ||
| -8.82% | 10.68B | A- | ||
| -2.20% | 8.59B | C | ||
| +15.12% | 7.09B | C | ||
| +26.97% | 5.07B | B+ | ||
| +7.09% | 3.39B | C- | ||
| +0.27% | 3.04B | B- | ||
| -10.28% | 2.02B | - | - | |
| -8.61% | 2B | - | ||
| -27.27% | 1.69B | - | C- |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- SYK Stock
- Ratings Stryker Corporation
